Also, the role of tumour necrosis factor α (TNF-α) as a neurotoxic agent in the pathogenesis of AD has been confirmed in clinical and animal studies, and researchers are continuing to seek TNF inhibitors that can cross the BBB, as the available TNF inhibitors on the market have no BBB permeability [18,19]. The gene discussed is TNF; the disease is Alzheimer disease.